ReviewBiomolecules2026
Host-Dependent Medicinal Quality of Taxilli Herba: A Comprehensive Review on Chemical Profiles and Bioactivities.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Taxilli Herba (Sangjisheng) is a hemi-parasitic medicinal plant whose quality is intrinsically linked to its host species. While previous reviews have extensively summarized its chemical constituents and pharmacological activities, a systematic understanding of how host trees dictate its quality and safety remains largely fragmented. This review bridges this gap by proposing a "host-governed quality paradigm." By integrating historical records with modern scientific findings, we critically evaluate the molecular mechanisms underlying host-parasite interactions and their impact on medicinal quality. We highlight that host species influence Taxilli Herba across three critical dimensions: (i) chemical composition, comprising both intrinsic bioactive compounds and host-derived metabolites; (ii) toxicity profile, where even hosts lacking cardiac glycosides may pose potential safety hazards; and (iii) pharmacological activity, where host identity modulates therapeutic potency and traditional medicinal properties (e.g., "cold" vs. "warm" nature). Importantly, we highlight that the cardiac glycoside test specified in the current Chinese Pharmacopoeia is insufficient to ensure the safety of Sangjisheng derived from diverse hosts. To address these challenges, we propose a host-governed quality paradigm comprising four pillars: (1) mechanistic studies on host-parasite interactions; (2) revision of pharmacopeial standards to restrict approved sources; (3) promotion of standardized cultivation using safe host species (e.g.,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.